Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement
April 24, 2018
Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license